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Summary
 
We investigated CD4
 
1
 
 and CD8
 
1
 
 T cell turnover in both healthy and HIV-1–infected adults
by measuring the nuclear antigen Ki-67 specific for cell proliferation. The mean growth frac-
tion, corresponding to the expression of Ki-67, was 1.1% for CD4
 
1
 
 T cells and 1.0% in CD8
 
1
 
T cells in healthy adults, and 6.5 and 4.3% in HIV-1–infected individuals, respectively. Analysis
of CD45RA
 
1
 
 and CD45RO
 
1
 
 T cell subsets revealed a selective expansion of the CD8
 
1
 
CD45RO
 
1
 
 subset in HIV-1–positive individuals. On the basis of the growth fraction, we de-
rived the potential doubling time and the daily turnover of CD4
 
1
 
 and CD8
 
1
 
 T cells. In HIV-
1–infected individuals, the mean potential doubling time of T cells was five times shorter than
that of healthy adults. The mean daily turnover of CD4
 
1
 
 and CD8
 
1
 
 T cells in HIV-1–infected
individuals was increased 2- and 6-fold, respectively, with more than 40-fold interindividual
variation. In patients with 
 
,
 
200 CD4
 
1
 
 counts, CD4
 
1
 
 turnover dropped markedly, whereas
CD8
 
1
 
 turnover remained elevated. The large variations in CD4
 
1
 
 T cell turnover might be rel-
evant to individual differences in disease progression.
 
D
 
uring the course of HIV-1 infection there is a pro-
gressive decrease of CD4
 
1
 
 T cells, but CD8
 
1
 
 T cells
usually remain at higher levels than those of uninfected in-
dividuals (1, 2). In late stage disease, both T cell popula-
tions decline rapidly (3). CD4
 
1
 
 T cell decrease has been
linked to the extent of viral replication (4), the efficacy of
the host immune response such as CD8
 
1
 
 T cell mediated
cytotoxicity (5–7), and apoptosis (8). In addition, late CD4
 
1
 
T cell depletion might result from a progressive exhaustion
through a continuously elevated T cell turnover (9).
T cell turnover in HIV-1–infected individuals has been
explored by two approaches, providing divergent results
(9–11). Ho et al. (9) and Wei et al. (10) studied T cell turn-
over after drug-induced disruption of quasi-steady state
viremia by measuring the slope of the CD4
 
1
 
 T cell rise in
the peripheral blood. They reported an increased daily
turnover of CD4
 
1
 
 lymphocytes estimated at 2 
 
3
 
 10
 
9
 
 cells
(9, 10). Wolthers et al. (11) evaluated CD4
 
1
 
 and CD8
 
1
 
 T
cell turnover by measuring telomere length as an indicator
of T cell replicative history. They reported shortening of
telomere length in CD8
 
1
 
 but not in CD4
 
1
 
 T cells of HIV-
1–infected individuals, and concluded that only CD8
 
1
 
 T
cells have an elevated turnover in HIV-1 infection (11).
Recently, Autran et al. (12) showed that during potent an-
tiviral therapy of HIV-1–infected patients there was an
early rise of CD45RO
 
1
 
 CD4
 
1
 
 T cells, suggesting a high
turnover of this subset in the pretreatment quasi-steady
state in HIV-1–infected patients. So far, the interpretation
of T cell turnover in HIV-1 infected individuals has been
hampered by the lack of data in healthy humans (13).
In this investigation, we determined T cell turnover in
HIV-1–infected individuals and healthy adults on the basis
of the T cell growth fraction as defined by the expression
of Ki-67 antigen, which is expressed exclusively in prolifer-
ating cells of human origin (14) during the late G1, S, G2,
or M phases of the cell cycle (15–17), with a short half-life
of 1 h (15). The protein with two polypeptide chains of
345 and 395 kD is encoded by a highly conserved region
on chromosome 10q25-ter (18). We determined Ki-67–
positive CD4
 
1
 
 and CD8
 
1
 
 T cells in HIV-1–infected indi-
viduals and healthy adults with three-color flow cytometry
analysis and calculated turnover of these T cell subsets on
the basis of their respective growth fraction and the T cell
blood concentration.
 
Materials and Methods
 
Study Subjects.
 
42 HIV-1–infected adult patients (cared for by
private practitioners, the Geneva AIDS Center, and the AIDS
consultation of the Ambilly Hospital) and 23 age-matched healthy
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adults (Geneva Blood Center) were included. None of the HIV-
1–infected patients had been seroconverting in the 12 mo preced-
ing enrollment and none of them had received antiretroviral
treatment in the 3 mo preceding enrollment. The HIV-1–infected
patients were stratified into subgroups according to their CD4
 
1
 
 T
cell levels (Table 1). HIV-1 RNA copies per milliliter of plasma
(viremia) was quantified by PCR (AMPLICOR HIV MONITOR;
Roche, Basel, Switzerland).
 
Cell Separation and Antibody Staining.
 
EDTA venous blood
samples were collected and processed within 4 h. PBMCs were
isolated by centrifugation on a Ficoll Hypaque density gradient
(GIBCO BRL, Gaithersburg, MD). For each assay, 2 
 
3
 
 10
 
5
 
 PBMCs
were incubated with fluorochrome-labeled specific monoclonal
antibodies against surface antigens for 15 min (monoclonal anti-
bodies CD3-PE, CD4-PE-Cy5, and CD8-PE-Cy5 supplied by
Immunotech, Marseille, France; and CD14-PE/CD45-FITC by
Dako, Glostrup, Denmark). After fixation and permeabilization
(19) with ORTHO PERMEAFIX
 
Ò
 
 (Ortho Diagnostic Systems,
Raritan, NJ), the cells were incubated for 40 min with Ki-67–FITC
(MIB-1) (Immunotech) or matching isotype controls. Antibodies
were used in the following combinations: CD3/CD4/Ki-67, CD3/
CD8/Ki-67, and CD14/CD45. In a subgroup of 9 age-matched
control blood donors and 16 HIV-1–infected patients, additional
combinations of CD4/CD45RA/Ki-67, CD4/CD45RO/Ki-67,
CD8/CD45RA/Ki-67, and CD8/CD45RO/Ki-67 were used. An-
tibodies were as follows: CD4-PE-Cy5, CD8-PE-Cy5, CD45RA-
PE clone ALB11, CD45RO-PE clone UCHL1, and Ki-67–FITC
(MIB-1) (all from Immunotech). After staining, cells were washed
in PBS and resuspended in 1% FCS, 1.5% BSA, 0.0015% sodium
azide, and 0.0055% NaEDTA in PBS.
 
Flow Cytometry.
 
The cells were immediately analyzed by
flow cytometry (Coulter EPICS XL2; Instrumentation Labora-
tory, Schlieren, Switzerland). At least 5,000 CD4
 
1
 
 or CD8
 
1
 
 T
cells and 2,500 cells of the CD45RA
 
1
 
/CD45RO
 
1
 
 subset were
counted. A large lymphocyte gate in the forward scatter/side scat-
ter diagram was used to include blasts, whereas a combination of
CD14/CD45 was used in parallel as control to exclude mono-
cytes (
 
,
 
2%). Gating of Ki-67
 
1
 
 cells was selected on the basis of
isotypic negative controls and positive controls with PHA-stimu-
lated PBMCs.
 
Cell Cycle Distribution of Ki-67
 
1
 
 Cells.
 
To determine cell cy-
cle distribution of Ki-67
 
1
 
 cells in infected and control individu-
als, parallel fluorescence-activated cell sorter analysis of T cells la-
beled with double combinations of CD4-FITC, Ki-67-FITC
(MIB-1), and propidium iodide (20) was performed in a sub-
group of nine HIV-1 infected individuals and four control blood
donors. In each assay, 2 
 
3
 
 10
 
5
 
 PBMCs were incubated with
monoclonal antibody CD4-FITC (Dako, Glostrup, Denmark) for
15 min and were permeabilized for 40 min as described above. In
a second tube, there was no incubation with CD4-FITC, but Ki-
67-FITC was added after permeabilization. After incubation with
Ki-67 for 40 min and two wash steps, propidium iodide was
added in the presence of RNase A (Sigma Chemical Co.), fol-
lowed by immediate FACS
 
Ò
 
 analysis. Thus, percentages of Ki-67
and cells in the S
 
2
 
GM phase within the CD4
 
1
 
 T cells could be
quantified, as well as the proportion of S
 
2
 
GM T cells expressing
Ki-67.
 
Calculation of Doubling Time and Turnover.
 
Lymphocyte pro-
liferation was assessed assuming that cells were in balanced expo-
nential growth, i.e., changing according to the equation 
 
dT
 
/
 
dt
 
 
 
5
a
 
 
 
p T
 
 
 
2
 
 
 
d T
 
 
 
5
 
 
 
0
 
, where 
 
a
 
 is the growth fraction determined by
Ki-67 (16, 17), 
 
p
 
 is the proliferation rate per cell, and 
 
d
 
 is the per
capita death rate. The population doubling time in the absence of
cell death is the potential doubling time, 
 
Dt
 
pot
 
, and can be deter-
mined by the equation 
 
Dt
 
pot
 
 
 
5
 
 
 
ln
 
 2 / (
 
a
 
 
 
p
 
). The cell proliferation
rate was taken from published data (21, 22). The turnover of T
cell populations was estimated based on two assumptions: first, we
assumed the T cell population was in quasi-steady state condition
(23), i.e., on a short timescale the number of cells produced each
day by proliferation was equal to the number being destroyed;
and second, we assumed that there was a dynamic exchange be-
tween lymphocytes in blood and peripheral tissues (24, 25), with
T cells in the blood being 2% of the total (26). The daily turnover
of T cells and their subsets in HIV-1–infected individuals and
control blood donors was calculated by multiplying 
 
a
 
 
 
p
 
 by the T
cell concentration per cubed millimeter, a factor taking into ac-
 
Table 1.
 
Concentration and Percentage (mean 
 
6
 
 SD) of CD4
 
1
 
 and CD8
 
1
 
 T Cells Expressing Ki-67
 
1
 
 in HIV-1–infected Individuals and 
Healthy Adults
 
HIV
 
1
 
HIV
 
2
 
,
 
200
 
*
 
 (
 
n
 
 
 
5
 
 15) 200–500 (
 
n
 
 
 
5
 
 10)
 
.
 
500 (
 
n
 
 
 
5
 
 17) Total (
 
n
 
 
 
5
 
 42) Total (
 
n
 
 
 
5
 
 23)
 
P
 
‡
 
CD4
 
1
 
/mm
 
3
 
71 
 
6
 
 64 374 
 
6 95 685 6 163 392 6 295 846 6 230
CD41 (%) 9.8 6 7.5 24.1 6 8.2 33.0 6 6.8 22.6 6 12.6 47.3 6 7.8
CD41Ki-671/mm3 6.1 6 5.7 19.1 6 12.3 24.5 6 12.9 16.6 6 13.3 8.9 6 5.1 ,0.001
CD41Ki-671 (%) 10.2 6 5.2 5.6 6 4.2 3.7 6 1.8 6.5 6 4.8 1.1 6 0.6 ,0.001
CD81/mm3 359 6 247 795 6 316 855 6 292 663 6 360 448 6 153
CD81 (%) 47.4 6 16.9 47.6 6 12.9 39.9 6 8.1 44.4 6 13.2 25.3 6 7.8
CD81Ki-671/mm3 18.8 6 17.3 31.5 6 28.7 28.9 6 17.6 25.9 6 20.8 4.2 6 3.0 ,0.001
CD81Ki-671 (%) 5.9 6 3.6 3.5 6 2.6 3.4 6 1.6 4.3 6 2.9 1.0 6 0.5 ,0.001
log HIV RNA/ml 5.0 6 0.9 4.2 6 1.1 3.8 6 0.8 4.4 6 1.0
*CD41 T cell concentration per mm3.
‡Mann-Whitney test: comparison between healthy adults and HIV-1–infected patients (total).1297 Sachsenberg et al.
HIV-1–infected individuals, growth fractions (percentage
of Ki-67) of CD41 (6.5 6 4.8%) and CD81 T cells (4.3 6
2.9%) were higher, with a wide variability, ranging from
1.1 to 18.6% in CD41 T cells and 0.7 to 11.4% in CD81 T
cells (Fig. 2, A and B). In healthy adults, growth fractions
of CD41 and CD81 T cells were associated (Wilcoxon
matched-pairs signed rank test; P 5 0.15), as well as in
HIV-1–infected patients, with .500 CD41 counts (P 5
0.46). The latter also had the lowest growth fractions (Ta-
ble 1). In contrast, both groups of patients with 200–500
CD41 counts and ,200 CD41 counts had higher growth
fractions that were not associated (P 5 0.008 and 0.005, re-
spectively).
When expressed in absolute numbers instead of percent-
ages, there were 8.9 6 5.1 CD41 lymphocytes/mm3 ex-
pressing Ki-67 in healthy individuals compared to 16.6 6
13.3 cells/mm3 in HIV-1–infected patients (Table 1). High
levels were detected in patients with .200 CD41 T cells/
mm3, whereas patients with ,200 CD41 T cells/mm3 had
less Ki-671CD41 cells/mm3 than healthy individuals (Ta-
ble 1). In controls, the concentration of proliferating CD81
lymphocytes was 4.2 6 3.0 cells/mm3, and these values
were increased in HIV-1–infected individuals by approxi-
mately sevenfold in the subgroups with .200 CD41 T
cells/mm3 and fourfold in patients with ,200 CD41 T
cells/mm3.
Growth Fractions of CD41 and CD81 T Cells Are Inversely
Correlated with the CD41 Count. In HIV-1–infected pa-
tients, expression of Ki-67 in CD41 lymphocytes was in-
versely correlated to the CD41 T cell concentration (Fig. 2
A) but remained constant at z1% in healthy controls over
a wide range of CD41 T cell concentrations (Fig. 2 A). Us-
ing regression analysis in infected patients, the fraction of
Ki-671, i.e., proliferating CD41 T cells, can be described
by the equation a 5 0.106 2 0.0001 T, where T is the
CD41 T cell concentration per mm3 and a is the prolifer-
ating fraction. Assuming that a similar relationship holds
within a single individual as CD41 counts change, an ap-
propriate description of CD41 T cell kinetics is given by
the equation (I):
,
where p is the per capita proliferation rate of CD41 T cells,
estimated to be 0.69 day21 and dT their per capita death
rate. In healthy individuals, the T cell death rate has been
estimated by McLean and Michie (27) to be 0.00014 day21,
and thus can be ignored compared with the other terms in
the equation. Thus, equation (I) predicts that, at steady
state, the CD41 cell concentration per mm3, T, is 1,060
cells/mm3, consistent with the average value found in
healthy adults. In HIV-1–infected patients, CD41 lympho-
cyte concentrations are lower and the CD41 T cell death
rate will be substantially elevated. For example, if T 5
200/mm3, then dT 5 0.059 day21 (by equation (I), at
steady state).
The growth fraction of CD81 lymphocytes (percentage
of Ki-671) did not correlate with the CD81 count in HIV-
dT/dt 0.106 ( 0.0001 T ) pT dTT – – =
Figure 1. Flow cytometry analysis of CD31CD41 and CD31
CD81cells stained with Ki-67. (A) Isotypic negative control (FITC). (B)
Expression of Ki-67 (percentage) in CD31CD41 T cells of a control
blood donor after a 48-h in vitro stimulation with phytohemagglutinin.
(C) Expression of Ki-67 (percentage) in CD31CD41 T cells of a control
blood donor with 950 CD41 T cells/mm3. (D) Expression of Ki-67 (per-
centage) in CD31CD41 T cells of a HIV-1–infected patient with 180
CD41 T cells/mm3.
count an estimated 5 liters total blood volume (5 3 106) and a
factor of 50 to extrapolate to total body T cells (26).
Statistical Analysis. The results are expressed as the mean 6 1
SD. All statistical analyses were performed with the SPSS soft-
ware. Statistical significance between patient groups and healthy
adults was analyzed with the Mann-Whitney U test. Significant
correlations were analyzed with the Spearman test. Comparison
of paired samples was performed with the Wilcoxon matched-
pairs signed-rank test.
Results
Detection of the Ki-67 Antigen in Proliferating T Cells. As
shown in Fig. 1, using triple labeling of PBMCs, CD31
CD41 T cells colabeled with Ki-67 antibodies are easily
identified, as are CD31CD81 T cells colabeled with Ki-67
(data not shown). After 48 h in vitro stimulation of PBMCs
of five uninfected controls with phytohemagglutinin, 60–70%
of the cells were Ki-67–positive (Fig. 1 B). In nine infected
and four control individuals, a high proportion (.60%) of
PBMCs expressing Ki-67 were in the SG2M phase, as de-
fined by propidium iodide labeling. There was a high cor-
relation (R .0.7; P 5 0.038) between Ki-67 expression
and propidium iodide staining in CD41 T cells in nine
HIV-1–infected individuals (data not shown).
Higher Expression of Ki-67 Found in CD41 and CD81 T
Cells in HIV-1–infected Individuals than in Healthy Adults.
In healthy adults, 1.1 6 0.6% of CD41 T cells and 1.0 6
0.5% of CD81 T cells were Ki-67–positive (Table 1). In1298 CD4 and CD8 Turnover in HIV-1–infected Persons
1–infected patients (Fig. 2 B), but was inversely correlated
(R 5 20.44; P 5 0.003) with the CD41 count (Fig. 3 A),
suggesting that low CD41 counts are associated with in-
creased proliferation of both CD41 and CD81 lympho-
cytes. Consistent with this interpretation, the growth frac-
tions of CD41 and CD81 lymphocytes were positively
correlated (R 5 0.62; P ,0.001; Fig. 3 B), suggesting that
proliferative factors act in parallel on both T cell subsets.
Lastly, the growth fraction of CD41 but not CD81 lym-
phocytes was correlated (R 5 0.43; P 5 0.006) with viral
load (data not shown) and with the logarithm of the viral
load (R 5 0.44; P 5 0.005; Fig. 3 C).
High Expression of Ki-67 in T Cells With the CD45RO1
Phenotype, and Expansion of Proliferating CD81CD45RO1T
Cells, but not of CD41CD45RO1 T Cells Are Found in HIV-
1–infected Individuals. The percentage of Ki-671 cells
(growth fraction) was two- to fourfold higher among
CD45RO1 cells than among CD45RA1 cells in CD41
and CD81 subsets in both 16 HIV-1–infected and 9
healthy adults (Fig. 4 A). In CD41 T cells of healthy adults,
Figure 2. Percentage of Ki-67 expression in CD41 and CD81 T cells in HIV-1–infected patients (filled triangles) and healthy adults (open squares) versus
absolute CD41 and CD81 counts. Regression lines are plotted for patient values only. (A) There is an inverse correlation between CD41 T cell count and ex-
pression of Ki-67 in CD41 T cells in HIV-1–infected patients (R 5 20.64; P ,0.001), but not in healthy adults (R 5 20.18; P 5 0.4). (B) HIV-1–infected
patients have higher absolute CD81 T cell counts and higher expression of Ki-67 in CD81 T cells than do healthy adults. There is no correlation be-
tween percentage of Ki-67 and CD81 count in HIV-1–infected patients (R 5 20.12; P 5 0.44) or in healthy adults (R 5 20.03; P 5 0.91).
Figure 3. Association between the percentage of Ki-67 expression, CD41 T cell concentration and viremia. (A) Significant negative correlation be-
tween the percentage of Ki-67–positive CD81 T cells and CD41 T cell concentration (R 5 20.44; P 5 0.003). (B) Significant positive correlation between
percentage of CD41Ki-671 and percent of CD81Ki-671 T cells (R 5 0.62; P ,0.001). (C) Positive correlation between percentage of Ki-67–positive
CD41 lymphocytes and the logarithm of the viral load (R 5 0.44; P 5 0.005).1299 Sachsenberg et al.
the median growth fraction was 0.8% in the CD45RA1
and 2.8% in the CD45RO1 subset. In CD81 T cells, the
corresponding values were 0.9 and 2.0%, respectively. As
expected, in HIV-1–infected individuals, there were ele-
vated median growth fractions in the CD45RO1 subsets of
6.7% in CD41 T cells and 6.8% in CD81 T cells. The me-
dian growth fraction in the CD45RA1 subsets was elevated
to 2.7% in CD41 T cells and to 1.7% in CD81 T cells,
compared with healthy adults. There was a significant cor-
relation between viral load and the percentage of Ki-67–
positive CD41CD45RO1 T cells (R 5 0.71; P 5 0.004)
and between viral load and percentage of Ki-67–positive
CD41CD45RA1 T cells (R 5 0.52; P 5 0.048) (data not
shown). In HIV-1–infected individuals, the concentration
of CD81CD45RO1/mm3 (median: 206 cells/mm3) was
increased twofold compared with healthy adults (median:
94 cells/mm3) (P 5 0.008), as shown in Fig. 4 C. Conversely,
the median of the concentration of CD41CD45RO1 T
cells in HIV-1–infected individuals was significantly de-
creased to 182 cells/mm3, compared with healthy adults
(median: 352 cells/mm3; P 5 0.008). There was a sixfold
elevated concentration of proliferating CD81CD45RO1 T
cells (median: 9.6 cells/mm3) in HIV-1–infected individuals
(Fig. 4 B) compared with controls (median: 1.7), whereas
the concentration of proliferating CD41CD45RO1 T cells
was only slightly elevated (median values: 14.0 in HIV-
1–infected individuals versus 8.9 cells/mm3 in controls),
despite similar growth fractions in both CD41CD45RO1
and CD81CD45RO1 subsets in HIV-1–infected individu-
als (Fig. 4 A).
Potential Doubling Time and Turnover of both CD41 and
CD81 T Lymphocytes Are Altered in HIV-1–infected Individu-
als. The mean potential doubling time of CD41 and
CD81 T cells was approximately five times shorter in HIV-
1–infected individuals than in healthy adults (Table 2). In
HIV-1–infected individuals with ,200 CD41 T cells/
mm3, the potential doubling time of CD41 T cells was
considerably shorter than in patients with higher CD41 T
cell concentrations. The same tendency was observed in
CD81 T cells, with the highest values of potential doubling
time in the group with 200–500 CD41 T cells/mm3 (Table
2). This observation is in line with more rapid T cell popula-
tion doublings in severely immunocompromised individuals.
The mean daily turnover of CD41 lymphocytes was cal-
culated at 1.5 6 0.9 3 109 cells in healthy individuals and
2.9 6 2.3 3 109 cells in HIV-1–infected patients, whereas
the corresponding mean daily CD81 T cell turnover was
0.7 6 0.53 3 109 and 4.5 6 3.6 3 109 cells/day, respec-
tively (Table 2). Compared with the mean control values,
10 out of 15 patients with ,200 CD41 counts had de-
creased CD41 T cell turnover (Table 2), despite high
growth fractions (Table 1). On the other hand, CD81 T
cell turnover remained elevated in this subgroup. Thus,
CD81 T cell turnover was elevated in all disease stages,
whereas CD41 T cell turnover fell below the values of
healthy adults in late stage disease. There was a significant
correlation between CD41 and CD81 T cell turnover in
both HIV-1–infected (R 5 0.69; P ,0.001) and control
individuals (R 5 0.53; P 5 0.009). A significant correlation
was also found between CD41 count and CD41 turnover
on the one hand and between CD81 count and CD81
turnover on the other in HIV-1–infected individuals, but
not in healthy adults (Fig. 5, A and B). There was no corre-
lation between CD41 count and CD81 turnover (data not
shown).
Figure 4. Higher expression of Ki-67 in CD45RO1 than in
CD45RA1 subsets of both CD41 and CD81 T cells are found in HIV-1–
infected individuals and in healthy adults. Results are depicted in box plot
diagrams, where the box represents the 25th and 75th quartile and the
line is the median value. Bars indicate 5th and 95th percentiles. (A)
Higher percentage of Ki-67 in CD45RO1 than CD45RA1 subsets of
CD41 and CD81 T cells in HIV-1–infected (Wilcoxon test, P 5 0.008
and P ,0.001, respectively) and healthy adults (P 5 0.008 and P 5 0.03,
respectively). (B) Absolute numbers of proliferating cells of the
CD45RA1 and CD45RO1 phenotype. There is no significant difference
between HIV-1–infected individuals and healthy adults for the
CD41CD45RA1 (Mann-Whitney U test, P 5 0.40), CD41CD45RO1
(P 5 0.22) and the CD81CD45RA1 subset (P 5 0.87), whereas Ki-67–
positive CD81CD45RO1 T cells are eightfold elevated in HIV-1–infected
individuals (P ,0.001). (C) Absolute numbers of CD41CD45RA1,
CD41CD45RO1, CD81CD45RA1, and CD81 CD45RO1 T cells in
HIV-1–infected and healthy adults. Significant differences between both
groups were found in the CD41CD45RO1 subset (P 5 0.006) and the
CD81CD45RO1 subset (P 5 0.007), but not in the CD41CD45RA1 (P
5 0.16) or the CD81CD45RA1 subset (P 5 0.31).1300 CD4 and CD8 Turnover in HIV-1–infected Persons
Discussion
In this study, we evaluated the CD41 and CD81 T cell
growth fraction in HIV-1–infected patients and healthy
adults as measured by expression of the nuclear antigen Ki-
67. In HIV-1–infected individuals, the mean increase in
CD41 T cell growth fraction (percentage of Ki-671 cells)
was around sixfold and that of CD81 T cells fourfold as
compared to healthy adults. There was a positive correla-
tion between CD41 and CD81 T cell growth fractions. In
addition, CD41 and CD81 T cell growth fractions were
inversely correlated with absolute CD41 counts. Thus,
proliferation of CD41 and CD81 T cells appears to be gov-
erned by similar mechanisms.
HIV-1–infected individuals had elevated levels of
CD81CD45RO1 T cells, as previously reported (28, 29).
In addition, we measured the levels of proliferating CD81
CD45RO1 T cells and found that they were raised sixfold
Table 2.  Potential Doubling Times and Daily Turnover Values (mean 6 SD) of CD41 and CD81 T Cells in HIV-1–infected Individuals 
and Healthy Adults. HIV-1–infected Patients Are Stratified into Three Subgroups According to CD41 T Cell Concentrations
HIV1 HIV2
,200* (n 5 15) 200–500 (n 5 10) .500 (n 5 17) Total (n 5 42) Total (n 5 23) P§
CD41 doubling time‡ 13.9 6 10.6 34.9 6 29.9 35.1 6 20.8 27.5 6 22.6 156.4 6 147.4 ,0.001
CD81 doubling time 25.4 6 16.9 50.3 6 41.2 38.0 6 19.1 36.4 6 26.5 166.9 6 134.7 ,0.001
CD41 turnoveri 1.05 6 0.98 3.30 6 2.14 4.24 6 2.23 2.88 6 2.31 1.54 6 0.88 0.029
CD81 turnover 3.25 6 2.99 5.45 6 4.98 5.02 6 3.04 4.49 6 3.61 0.73 6 0.51 ,0.001
*CD41 T cell concentration per mm3.
‡In days.
§Mann-Whitney U-test: comparison between healthy adults and HIV-1–infected patients (total).
iNumber 3 109 cells per day.
Figure 5. Daily T cell turnover (3109) versus T cell concentration in HIV-1–infected patients (filled triangles) and healthy adults (open squares). Regres-
sion lines are plotted for patient values only. (A) CD41 T cells: there is a tendency to higher turnover in HIV-1–infected individuals (2.88 6 2.31) than
in healthy adults (1.54 6 0.88). CD41 T cell turnover is positively associated with CD41 T cell concentration (R 5 0.66, P ,0.001) in HIV-1–infected
individuals, but not in healthy adults (R 5 0.29; P 5 0.19). (B) CD81 T cell turnover is increased up to 15-fold in HIV-1–infected individuals (4.49 6
3.61) compared with values of healthy adults (0.73 6 0.51). There is also a positive correlation between CD81 T cell turnover and CD81 T cell concen-
tration in HIV-1–infected individuals (R 5 0.68; P ,0.001), but not in healthy adults (R 5 0.38; P 5 0.08).1301 Sachsenberg et al.
as compared to healthy adults, possibly reflecting an anti-
gen-driven expansion of this subset (30). These findings sug-
gest that under steady-state conditions, the elevated pro-
duction of CD81CD45RO1 T cells is counterbalanced by
high death rates of this subset, probably due to apoptosis (31).
In contrast, the levels of CD41CD45RO1 T cells in HIV-
1–infected individuals were below those of healthy adults,
despite a growth fraction as high as that of CD81CD45RO1
T cells. The lack of expansion of CD41CD45RO1 T cells
may partly be due to direct or indirect virus-mediated de-
struction (32). We found a positive correlation between vi-
ral load and CD41CD45RO1 T cell growth fraction, sug-
gesting that the high growth fraction of CD41CD45RO1
T cells might account in part for the early rise in CD41 T
cell counts observed after initiation of potent antiviral treat-
ment (12).
The issue of T lymphocyte turnover is central to the un-
derstanding of HIV-1 pathogenesis (33). We estimate that
HIV-1–infected individuals have a mean sixfold increase of
CD81 T cell turnover, whereas the mean turnover of
CD41 T cells only increases by twofold. The higher turn-
over of CD81 T cells reflects the inversion of the CD41/
CD81 ratio in HIV-1–infected patients (3). Differences in
CD41 and CD81 T cell turnover also depend on the dis-
ease stage, as defined by CD41 T cell counts. Whereas
CD81 T cell turnover remained high during all stages of
disease, CD41 T cell turnover dropped below the normal
levels as measured in healthy adults in patients with CD41
counts below 200/mm3. In these patients, progressive
CD41 T cell loss occurred in spite of the high proliferative
activity of CD41 T cells.
Recent studies based on measurements of telomere
length failed to detect changes in CD41 T cell turnover in
HIV-1–infected patients (11), in contrast to the data re-
ported here. Possible explanations for this divergence in-
volve patient selection and sensitivity of telomere length
measurements. A two- to threefold increase in CD41 T
cell turnover might be too small for detection based on
changes in telomere length. In addition, changes in telo-
mere length may insufficiently reflect the degree of prolif-
eration in cell populations in which dividing cells are rapidly
destroyed. In a study of twins heterogeneous for HIV-1
infection, telomere length in CD41 T cells was signifi-
cantly greater in the HIV-1–infected twin (34), supporting
the idea of abnormal population dynamics or telomerase
activity skewing the results (35). Previous studies, based on
CD41 T cell recovery after initiation of potent antiviral
treatment, reported a high CD41 T cell turnover of 2 3
109 cells daily (9, 10). The data reported here are consistent
with this rate of CD41 T cell turnover, but also show that
CD41 T cell turnover is only increased twofold in HIV-
1–infected individuals, as compared to healthy individuals.
We also confirmed the wide interindividual variability in
CD41 T cell growth and turnover rates that might mirror
individual differences in disease progression. The impres-
sive eightfold increase in CD81 T cell turnover in HIV-1
patients described here is consistent with the data derived
from the measurement of telomere length (11).
The rapid rise in CD41 counts after initiation of potent
antiviral therapy (9, 10) may be explained by two mecha-
nisms: first, by an inhibition of virus-mediated CD41 T cell
destruction in the presence of an ongoing elevated CD41
T cell production (9, 10); and second, by a release of CD41
T cells from lymphoid tissues into blood (36, 37). The high
mean production of CD41 T cells we observed in HIV-1–
infected individuals may be sufficient to raise CD4 counts
independent of redistribution. Moreover, our study was
performed without causing any perturbation of the steady
state between lymphocyte distribution in lymphoid tissues
and peripheral blood. However, our estimates on total
body T cell turnover were derived from the measurement
of Ki-671 T cells in the peripheral blood and should be
further explored by studies in lymph nodes.
In patients with low CD41 counts high viral loads were
accompanied by diminished CD41 T cell turnover values,
as compared to healthy adults. In contrast, in patients with
higher CD41 counts there were lower viral loads and ele-
vated CD41 T cell turnover values. Given the in vitro esti-
mates that one infected CD41 T cell can produce up to 102
infectious virus and up to 105 noninfectious virus particles
(38, 39), the number of CD41 T cells required to produce
the minimal estimate of 1010 to 1011 virions per day (40)
represents a small fraction of the 2–7 3 109 CD4 T cells
produced each day in patients with .200 CD41 T cells
(Table 2, Fig. 5 A). In patients with ,200 CD41 counts, a
lower production of z109 CD41 T cells is associated with
higher viral loads. Thus, virus-mediated destruction may
substantially contribute to CD41 T cell depletion in pa-
tients with very low CD41 counts, whereas other mecha-
nisms such as apoptosis (8, 41) or CTL-mediated lysis (5–7)
would play a predominant role in patients with .200
CD41 counts.
In conclusion, our study shows elevated turnover of CD81
T cells and to a lesser extent CD41 T cells in HIV-1–infected
patients. The large expansion of CD81CD45RO1 T cells in
the absence of a comparable expansion of CD41CD45RO1
T cells, despite similar growth characteristics, contributes to
the imbalance of T cell populations in HIV-1 infection.
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